Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H22N10O3 |
| Molecular Weight | 510.5074 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NN=NN1N=CC2=CC(C(C3=CC=C(O)C=C3)C4=CC(C=NN5N=NN=C5C)=CC=C4O)=C(O)C=C2
InChI
InChIKey=BLUJRJMLDHEMRX-UHFFFAOYSA-N
InChI=1S/C25H22N10O3/c1-15-28-30-32-34(15)26-13-17-3-9-23(37)21(11-17)25(19-5-7-20(36)8-6-19)22-12-18(4-10-24(22)38)14-27-35-16(2)29-31-33-35/h3-14,25,36-38H,1-2H3
VP-14637 (also known as MDT 637) was developed as an inhibitor of respiratory syncytial virus (RSV). RSV is the leading cause of respiratory tract infections in humans. VP-14637 participated in phase I clinical trial to evaluate the safety and pharmacokinetic profile of the drug in healthy human volunteers. However, further study was discontinued because of the strategic decision.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
235106-62-4
Created by
admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
|
PRIMARY | |||
|
DTXSID10946228
Created by
admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
|
PRIMARY | |||
|
135565536
Created by
admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
|
PRIMARY | |||
|
HCW4G0O030
Created by
admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
|
PRIMARY | |||
|
DB12195
Created by
admin on Fri Dec 15 16:15:41 GMT 2023 , Edited by admin on Fri Dec 15 16:15:41 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
